E
Emily C. Zabor
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 145
Citations - 5297
Emily C. Zabor is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 32, co-authored 125 publications receiving 3963 citations. Previous affiliations of Emily C. Zabor include New York University & University of Southern California.
Papers
More filters
Journal ArticleDOI
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer
Tanaya Shree,Oakley C. Olson,Benelita T. Elie,Jemila C. Kester,Alfred L. Garfall,Kenishana Simpson,Katherine M. Bell-McGuinn,Emily C. Zabor,Edi Brogi,Johanna A. Joyce +9 more
TL;DR: Increased macrophage infiltration and cathepsin protease levels in mammary tumors following paclitaxel (Taxol) chemotherapy are found and this study highlights the importance of integrated targeting of the tumor and its microenvironment and implicates macrophages andCathepsins in blunting chemotherapeutic response.
Journal ArticleDOI
Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer
Gopa Iyer,Hikmat Al-Ahmadie,Nikolaus Schultz,Aphrothiti J. Hanrahan,Irina Ostrovnaya,Arjun Vasant Balar,Philip H. Kim,Oscar Lin,Nils Weinhold,Chris Sander,Emily C. Zabor,Manickam Janakiraman,Ilana Rebecca Garcia-Grossman,Adriana Heguy,Agnes Viale,Bernard H. Bochner,Victor E. Reuter,Dean F. Bajorin,Matthew I. Milowsky,Barry S. Taylor,David B. Solit +20 more
TL;DR: The prevalence and co-occurrence of actionable genomic alterations in patients with high-grade bladder cancer are defined to serve as a platform for therapeutic drug discovery and optimal development of target-specific agents will require pretreatment genomic characterization.
Journal ArticleDOI
An Epidemiologic and Genomic Investigation Into the Obesity Paradox in Renal Cell Carcinoma
A. Ari Hakimi,Helena Furberg,Emily C. Zabor,Anders Jacobsen,Nikolaus Schultz,Giovanni Ciriello,Nina Mikklineni,Brandon Fiegoli,Philip H. Kim,Martin H. Voss,Hui Shen,Peter W. Laird,Chris Sander,Victor E. Reuter,Robert J. Motzer,James J. Hsieh,Paul Russo +16 more
TL;DR: The findings suggest that although BMI is not an independent prognostic factor for CSM after controlling for stage and grade, tumors developing in an obesogenic environment may be more indolent.
Journal ArticleDOI
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.
Min Yuen Teo,Richard Martin Bambury,Emily C. Zabor,Emmet Jordan,Hikmat Al-Ahmadie,Mariel Elena Boyd,Nancy Bouvier,Stephanie A. Mullane,Eugene K. Cha,Nitin Roper,Irina Ostrovnaya,David M. Hyman,Bernard H. Bochner,Maria E. Arcila,David B. Solit,Michael F. Berger,Dean F. Bajorin,Joaquim Bellmunt,Gopakumar Iyer,Jonathan E. Rosenberg +19 more
TL;DR: Somatic DDR alteration is associated with improved clinical outcomes in platinum-treated patients with advanced urothelial carcinoma and once validated, it can improve patient selection for clinical practice and future study enrollment.
Journal ArticleDOI
Efficacy of Exercise Therapy on Cardiorespiratory Fitness in Patients With Cancer: A Systematic Review and Meta-Analysis.
Jessica M. Scott,Emily C. Zabor,Emily Schwitzer,Graeme J. Koelwyn,Scott C. Adams,Tormod S. Nilsen,Chaya S. Moskowitz,Konstantina Matsoukas,Neil M. Iyengar,Chau T. Dang,Lee W. Jones +10 more
TL;DR: Exercise therapy is an effective adjunctive therapy to improve CRF in patients with cancer and support the recommendation of exercise therapy for patients with adult-onset cancer.